Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Parkinson's Disease With Cognitive Impairments
Interventions: safinamide, placebo; Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 9
States / cities: Sunnyvale, California • Jacksonville, Florida • Atlanta, Georgia + 5 more

Conditions: Enhanced Recovery After Surgery in a Pediatric Population
Interventions: Caffeine citrate 15mg/kg, 0.9% Sodium Citrate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 3 Years to 12 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteer
Interventions: ABBV-859, Placebo for ABBV-859; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Abortion
Interventions: Digoxin, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Long Beach, California • San Francisco, California • Portland, Oregon

Conditions: Inflammation, Obesity, Pregnancy, Fetal Growth
Interventions: Omega-3 Fish Oil; Dietary Supplement
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anxiety
Interventions: CES treatment using Alpha-Stim technology, Shame CES Treatment; Device
Lead sponsor: Wyndhurst Counseling Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Lynchburg, Virginia

Conditions: Traumatic Brain Injury
Interventions: Placebo, Sertraline; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Idiopathic Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 10
States / cities: Gilbert, Arizona • Sunnyvale, California • Tampa, Florida + 7 more

Conditions: Schizophrenia, Mental Disorders, Psychotic Disorders
Interventions: THC and Iomazenil, Placebo (control); Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Pirfenidone, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III
Interventions: omega-3 fatty acid, placebo, Questionnaire administration; Dietary Supplement · Other · Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Duchenne Muscular Dystrophy
Interventions: Pamrevlumab, Placebo, Corticosteroids; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 6 Years to 11 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 27
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 24 more

Conditions: Alcohol Drinking
Interventions: Dietary Fiber + Green Tea Extract, Alcohol, Aspartame Placebo Supplement; Dietary Supplement · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Carcinoma, Hepatocellular
Interventions: Mapatumumab, Placebo, Sorafenib; Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 9
States / cities: Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more

Conditions: Aphthous Stomatitis
Interventions: multivitamin; Dietary Supplement
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Shoulder Joint Disease, Complications; Arthroplasty, Intraoperative Complications, Blood Loss, Surgical
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Hip Fractures, Blood Loss
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
Interventions: SER-252 (PEOZ-apomorphine), enFuse; Drug · Device
Lead sponsor: Serina Therapeutics; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Englewood, Colorado • Hallandale, Florida • Maitland, Florida + 1 more

Conditions: Colorectal Cancer
Interventions: Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 49
States / cities: Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more

Conditions: Wheezing, Asthma in Children
Interventions: Soy isoflavone, matching placebo; Drug
Lead sponsor: Rajesh Kumar; Other
Eligibility: 2 Months to 12 Months
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Clemastine, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Borderline Hypokalemia
Interventions: K+ supplement, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 30 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Allergic Conjunctivitis
Interventions: hydrocortisone ophthalmic ointment 0.5%, placebo; Drug
Lead sponsor: Koffler Vision Group; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Feeding Delays, Neonates and Term Infants
Interventions: taVNS, NAC and taVNS, inactive taVNS, sterile water and inactive taVNS; Device · Combination Product
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 39 Weeks to 54 Weeks
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

Dex +/- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population

A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation

Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy

Use of Alpha-Stim Cranial-electrotherapy Stimulation (CES) in the Treatment of Anxiety

Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury

Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Effects of Delta-9-THC and Iomazenil in Healthy Humans

Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Satiety and Alcohol Challenge

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Prevention of Recurrent Aphthous Stomatitis Using Vitamins

Tranexamic Acid in Reverse Total Shoulder Arthroplasty

Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

The Effects of Potassium on Glucose Metabolism in African Americans

Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis

BabySTrong II taVNS Feeding Trial